For World Immunization Week, Pharmacy Times® interviewed Nurisha Wade, MBA, VP of Global Healthcare Quality & Safety Center of Excellence at US Pharmacopeia (USP), and Farah Towfic, PharmD, MBA, director, CEO of Operations at USP, on USP’s COVID-19 Vaccine Handling Toolkit.
Pharmacy Times® interviewed Scott J. Knoer, MS, PharmD, FASHP, the EVP and CEO of the American Pharmacists Association, on the Pharmacy and Medically Underserved Area Enhancement Act that was recently introduced in Congress.
A discussion on the extrapolation of European data to aid in P&T (Pharmacy and Therapeutics) committee decisions to adopt the use of biosimilars.
Pharmacy Times® interviewed Amy Snyder, a member at Eckert Seamans Cherin & Mellott, on the implications for pharmacy of mandated COVID-19 vaccinations in higher education institutions.
Just as pharmacists have been on the front lines of the COVID-19 pandemic, Kristen Lund, CPhT, a technician at Hy-Vee Pharmacy in Harlan, Iowa, said technicians have taken on greater responsibilities and have become more involved in patient care.
Pharmacy Times® interviewed Dennis O’Neill, president and board member of Biomedican, to discuss how providers are looking to psychedelic medicine to treat certain mental health disorders.
Experts share insights on how they have utilized Prescription Monitoring Programs to combat the opioid crisis and improve the safety of prescribed opioids.
Experts share approaches to normalize conversations about naloxone with patients, as well as share important considerations for maximizing naloxone education.
Experts discuss managing biosimilar adoption in various clinical practice settings, working through the P&T (Pharmacy and Therapeutics) approval process, and the importance of relying on a shared-decision making framework.
Pharmacy Times spoke with spinal muscular atrophy (SMA) patient Nick Sinagra about his treatment journey and his experiences with 2 different SMA treatments.
Pharmaceutical companies have already begun developing these boosters, and Haydock said he expects to see some variant-specific vaccines available by mid-2021.
Multidisciplinary panel of clinicians discuss whether recommendations made by national, state, and local agencies infringes upon clinical practice autonomy.
Ryan Haumschild, PharmD, MS, MBA, provides insight on biosimilar adoption both in oncology and non-oncology practice settings.
Jeffrey Bratberg, PharmD, FAPhA, and Joshua Lynch, DO, EMT-P, FAAEM, FACEP, discuss highlights from the December 2020 CDC Health Alert and application.
As the FDA and CDC have paused use of the Johnson & Johnson COVID-19 vaccine in the United States, research is ongoing to understand whether cerebral venous sinus thrombosis (CVST) is directly linked to the vaccine.
The impact on biosimilar utilization in clinical practice caused by secondary patents of biologics and skinny labels of biosimilars is discussed.
Over the past 18 months, the FDA has approved 4 new regimens for HER2-positive metastatic disease.
Madeline Camejo, PharmD, and Estela Trimino, PharmD, BCPS, discuss the emerging role of the pharmacist on the front line of vaccine administration.
Health system pharmacists discuss challenges with the COVID-19 vaccine rollout, such as having multiple vaccine types and lot numbers on hand and appointment no-shows
Megan May, PharmD, BCOP, Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, share their thoughts on unmet needs in the management of neuroendocrine tumors.
The experts discuss measures taken by pharmacy to prevent waste of vaccine doses and the education provided to members of the medical staff.
Madeline Camejo, PharmD, MS, leads discussion on vaccination of health care workers and the strategies implemented at their institutions to accomplish this task.
Madeline Camejo, PharmD, MS, and Michael Epshteyn, PharmD, MSM, discuss pharmacy’s involvement in the COVID-19 vaccine rollout and training pharmacists to be vaccinators.
Tim Peterson, PharmD, BCOP, leads the discussion on immunogenicity testing and lot-to-lot variability, including the potential impact on the safety and efficacy of reference biologics and their biosimilars.
Patricia Stinchfield, the president-elect of National Foundation for Infectious Diseases, discusses the recommended framework for vaccine messaging for leaders across sectors.
As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape.
Hager Hanon, PharmD, RPh, senior pharmacist at Community Care Rx, discusses COVID-19 vaccination hesitancy among pregnant women and people with a history of anaphylaxis.
A discussion on what it means for a biosimilar to have “interchangeability” status and its potential impact on biosimilar adoption in clinical practice.
A panel of experts in neuroendocrine tumors review the challenges in the management of patients based on the site of the tumor.
Experts address barriers to overcome regarding naloxone prescribing, dispensing, and utilization that they have seen in the community.
